Stockreport

Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-C...

PORTOLA PHARMACEUTICALS  (PTLA) 
Last portola pharmaceuticals earnings: 2/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.portola.com
PDF – Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Sign [Read more]